<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="31960"><DrugName>BL-1829</DrugName><DrugSynonyms><Name><Value>BL-1829</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="23328">Bioglan Pharmaceuticals Co</CompanyOriginator><CompaniesSecondary><Company id="23328">Bioglan Pharmaceuticals Co</Company></CompaniesSecondary><CrossReferences><SourceEntity id="23328" type="Company"><TargetEntity id="4297086785" type="organizationId">IGuard Inc</TargetEntity></SourceEntity><SourceEntity id="1005" type="ciIndication"><TargetEntity id="1570" type="siCondition"></TargetEntity><TargetEntity id="4148" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="287" type="Action"><TargetEntity id="270" type="Mechanism">Opioid Receptor Agonists</TargetEntity><TargetEntity id="2414" type="Mechanism">epsilon-Opioid Receptor Agonists</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="1005">Unidentified indication</Indication></IndicationsSecondary><ActionsPrimary><Action id="287">Opioid receptor agonist</Action></ActionsPrimary><Technologies><Technology id="617">Aerosol formulation inhalant</Technology><Technology id="616">Inhalant formulation</Technology><Technology id="680">Buccal formulation systemic</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-08-22T05:31:05.000Z</LastModificationDate><ChangeDateLast>2004-02-11T17:53:08.000Z</ChangeDateLast><AddedDate>2000-12-11T15:46:05.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="31960" linkType="Drug"&gt;BL-1829&lt;/ulink&gt; is a sublingual formulation of an opioid agonist, which was under investigation by Bioglan for unspecified indications [&lt;ulink linkID="390343" linkType="reference"&gt;390343&lt;/ulink&gt;]. Bioglan went into administration in February 2002 [&lt;ulink linkID="446057" linkType="reference"&gt;446057&lt;/ulink&gt;], and by February 2004, had gone into liquidation [&lt;ulink linkID="521149" linkType="reference"&gt;521149&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="23328">Bioglan Pharmaceuticals Co</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1005">Unidentified indication</Indication><StatusDate>2002-02-01T00:00:00.000Z</StatusDate><Source id="446057" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="23328">Bioglan Pharmaceuticals Co</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1005">Unidentified indication</Indication><StatusDate>2000-12-11T15:46:06.000Z</StatusDate><Source id="390343" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01453"><Name>Opioid receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></drugRecordOutput>